Myelofibrosis (MF) waxaa loo yaqaan myelofibrosis.Sidoo kale waa cudur aad dhif u ah.Sababta keentayna lama garanayo.Calaamadaha caafimaad ee caadiga ah waa unugga dhiigga cas ee dhalinyarada iyo anemia granulocytic anemia oo leh tiro badan oo ah jeexjeexa unugyada dhiigga cas.Hamiga dhuuxa lafta ayaa inta badan muujiya hammi qallayl, beeryarada ayaa inta badan si muuqata u weynaysa iyada oo leh heerar kala duwan oo lafo-osteosclerosis ah.
Myelofibrosis aasaasiga ah (PMF) waa xanuunka 'clonal myeloproliferative disorder' (MPD) ee unugyada tarma ee hematopoietic.Daawaynta myelofibrosis aasaasiga ah ayaa ugu horayn taageero ah, oo ay ku jirto dhiig ku shubid.Hydroxyurea waxaa lagu siin karaa thrombocytosis.Khatarta hoose, bukaanada asymptomatic-ka ah waa la arki karaa daaweyn la'aan.
Laba daraasadood oo kala duwan oo weji III ah (STUDY1 iyo 2) ayaa lagu sameeyay bukaannada qaba MF (MF aasaasiga ah, post-geniculocytosis MF, ama trombocythemia post-primary trombocythemia MF).Labada daraasadoodba, bukaannada is-diiwaangeliyay waxay lahaayeen splenomegaly la dareemi karo ugu yaraan 5 cm oo ka hooseeya qafiska feeraha waxayna ahaayeen kuwo dhexdhexaad ah (2 arrimood oo saadaalin ah) ama khatar sare (3 ama arrimo ka badan oo saadaalin ah) sida waafaqsan shuruudaha la isku raacsan yahay ee Kooxda Shaqada Caalamiga ah (IWG).
Qiyaasta bilowga ah ee ruxolitinib waxay ku salaysan tahay tirada platelet.15 mg laba jeer maalintii bukaanada qaba platelet waxay tiriyaa inta u dhaxaysa 100 iyo 200 x 10^9/L iyo 20 mg laba jeer maalintii bukaanada qaba platelet waxay tiriyaan in ka badan 200 x 10^9/L.
Qiyaaso gaar ah ayaa la siiyay iyadoo loo eegayo dulqaadka iyo waxtarka bukaanada qaba tirooyinka platelet inta u dhaxaysa 100 iyo 125 x 10 ^ 9 / L, oo ​​leh qiyaasta ugu badan ee 20 mg laba jeer maalintii;Bukaannada qaba platelet waxay tiriyaan inta u dhaxaysa 75 iyo 100 x 10^9/L, 10 mg laba jeer maalintii;iyo bukaanada qaba platelet waxay tiriyaa inta u dhaxaysa 50 iyo in ka yar ama la mid ah 75 x 10^9/L, 2 jeer maalin kasta 5mg mar kasta.
Ruxolitinibwaa afka laga qaato JAK1 iyo JAK2 tyrosine kinase inhibitor oo lagu ansixiyay Midowga Yurub Ogosto 2012 si loogu daweeyo myelofibrosis dhexdhexaad ah ama khatar sare leh, oo ay ku jiraan myelofibrosis aasaasiga ah, post-geniculocytosis myelofibrosis iyo post-primary thrombocythemia myelofibrosis.Waqtigan xaadirka ah, ruxolitinib Jakavi waxaa laga ansixiyay in ka badan 50 waddan oo adduunka ah, oo ay ku jiraan Midowga Yurub, Kanada iyo dhowr waddan oo Aasiya, Laatiin iyo Koonfurta Ameerika ah.